Exacerbations · autumn asthma exacerbations in children
Omalizumab probably leads to lower exacerbations compared with usual care (moderate certainty).
3 findings from 1 review
OR 0.48 [0.25, 0.92]
1 study · 348 participants
Moderate
OR 0.37 [0.17, 0.81]
1 study · 184 participants
Moderate
OR 0.63 [0.22, 1.79]
1 study · 164 participants
Moderate
Exacerbations · autumn asthma exacerbations in children
The review found no eligible studies for this question.
2 findings from 1 review
Adverse events · autumn asthma exacerbations in children
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · autumn asthma exacerbations in children
Omalizumab showed no clear difference in adverse events compared with usual care (moderate certainty).
1 finding from 1 review
Exacerbations · autumn asthma exacerbations in children
A boost of inhaled corticosteroids showed no clear difference in exacerbations compared with usual care (moderate certainty).
1 finding from 1 review
Adverse events · autumn asthma exacerbations in children
A boost of inhaled corticosteroids showed no clear difference in adverse events compared with usual care (moderate certainty).
1 finding from 1 review
Exacerbations · autumn asthma exacerbations in children
The review found no eligible studies for this question.
2 findings from 1 review
Adverse events · autumn asthma exacerbations in children
Leukotriene receptor antagonist showed no clear difference in adverse events compared with usual care (high certainty).
1 finding from 1 review
Health‐related quality of life · people with non‐cystic fibrosis bronchiectasis
2 findings from 1 review
Exacerbations requiring antibiotics · people with non‐cystic fibrosis bronchiectasis
The review found no eligible studies for this question.
1 finding from 1 review
Serious adverse events: mortality · people with non‐cystic fibrosis bronchiectasis
1 finding from 1 review
Hospital admissions · people with non‐cystic fibrosis bronchiectasis
1 finding from 1 review
Lung function · people with non‐cystic fibrosis bronchiectasis
1 finding from 1 review
Self‐efficacy · people with non‐cystic fibrosis bronchiectasis
1 finding from 1 review
Costs · people with non‐cystic fibrosis bronchiectasis
The review found no eligible studies for this question.
1 finding from 1 review
All‐cause mortality · patients with stable angina pectoris
It is very uncertain whether exercise‐based cardiac rehabilitation changes all‐cause mortality compared with usual care (very low certainty).
1 finding from 1 review
Acute myocardial infarction · patients with stable angina pectoris
It is very uncertain whether exercise‐based cardiac rehabilitation changes acute myocardial infarction (AMI) compared with usual care (very low certainty).
1 finding from 1 review
Exercise capacity · patients with stable angina pectoris
1 finding from 1 review
Cardiovascular hospital admissions · patients with stable angina pectoris
It is very uncertain whether exercise‐based cardiac rehabilitation changes cardiovascular‐related hospital admissions ( compared with usual care (very low certainty).
1 finding from 1 review
Health‐related quality of life ( · patients with stable angina pectoris
1 finding from 1 review